Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
5.310
+0.090 (+1.72%)
Streaming Delayed Price
Updated: 10:33 AM EDT, Apr 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sagimet Biosciences Inc. - Series A Common Stock
< Previous
1
2
3
Next >
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 11, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
February 25, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
February 05, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 02, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
January 08, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
December 18, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
December 17, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 10, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
November 20, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
November 10, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
October 14, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
October 07, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
October 01, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
September 24, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
September 17, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
September 10, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
August 26, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 13, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 05, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
June 09, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
June 04, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
May 22, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 08, 2025
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
April 23, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
March 12, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
March 11, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
February 19, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
